10 Best Biotech Stocks to Buy Under $10

8. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Number of Hedge Fund Holders: 21 

Share Price: $4.77 

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotechnology company integrating artificial intelligence (AI), machine learning, and high-throughput biology to accelerate drug discovery. Its proprietary platform, Recursion OS, is central to advancing therapies in oncology and rare diseases.

In 2025, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) partnered with MIT to launch Boltz-2, an AI model trained on its BioHive-2 platform to predict small molecule–protein binding with high precision. This breakthrough could shorten drug discovery timelines and strengthen its leadership in AI-driven bioengineering. The business also rolled out Recursion OS 2.0 and expanded collaborations with Tempus and HealthVerity to leverage multimodal datasets.

A major strategic shift came with the merger with Exscientia, combining Exscientia’s small molecule design expertise and pipeline with the firm’s AI platform. This transformative move highlights why RXRX is often included among the best biotech stocks, given its strong positioning in AI-enabled drug discovery. To streamline operations, the company discontinued several programs and focused on six core candidates, four in oncology and two in rare diseases. Lead programs include REC-617, a CDK7 inhibitor in cancer, and REC-4881, targeting familial adenomatous polyposis.

In July 2025, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) expanded its rare disease pipeline by acquiring REV102, an oral ENPP1 inhibitor for hypophosphatasia (HPP), a disorder with no existing oral treatments. This positions the corporation to address a critical unmet need.

With multiple clinical trial initiations and data readouts expected in late 2025, alongside its strengthened AI capabilities and partnerships with global pharma leaders like Roche, Sanofi, Bayer, and Merck KGaA, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is positioned as a frontrunner in AI-driven drug discovery and development.